{"entity":{"id":"nct05208944","kind":"trial","name":"THIO Sequenced With Cemiplimab in Advanced NSCLC","aka":[],"tldr":"A phase 2 trial of Cemiplimab in non-small-cell lung cancer, run by Maia Biotechnology, active and no longer recruiting.","summary":"THIO Sequenced With Cemiplimab in Advanced NSCLC is a phase 2 interventional study registered as NCT05208944 by Maia Biotechnology, with 227 participants enrolled, started 2022-06-08 and due to reach its primary completion in 2027-09-30. Interventions recorded: 6-Thio-2'-Deoxyguanosine and Cemiplimab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05208944","url":"https://clinicaltrials.gov/study/NCT05208944"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["cemiplimab"],"companies":["maia-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05208944","phase":"2","setting":"A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced With Cemiplimab (LIBTAYO®) in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Maia Biotechnology","enrolled":227,"outcomes":[]},"route":"/trials/nct05208944/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"company":[{"id":"maia-biotechnology","kind":"company","name":"Maia Biotechnology","route":"/companies/maia-biotechnology/"}]}}